Reported Earnings • Apr 07
Full year 2026 earnings released: EPS: JP¥339 (vs JP¥301 in FY 2025) Full year 2026 results: EPS: JP¥339 (up from JP¥301 in FY 2025). Revenue: JP¥55.0b (up 14% from FY 2025). Net income: JP¥1.28b (up 13% from FY 2025). Profit margin: 2.3% (in line with FY 2025). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth. 공지 • Apr 06
Medical Ikkou Group Co.,Ltd., Annual General Meeting, May 20, 2026 Medical Ikkou Group Co.,Ltd., Annual General Meeting, May 20, 2026. 공지 • Apr 02
Medical Ikkou Group Co.,Ltd. to Report Fiscal Year 2026 Results on Apr 06, 2026 Medical Ikkou Group Co.,Ltd. announced that they will report fiscal year 2026 results on Apr 06, 2026 Buy Or Sell Opportunity • Mar 24
Now 21% overvalued Over the last 90 days, the stock has fallen 1.3% to JP¥2,823. The fair value is estimated to be JP¥2,336, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 18% over the last 3 years. Earnings per share has grown by 14%. Upcoming Dividend • Feb 19
Upcoming dividend of JP¥60.00 per share Eligible shareholders must have bought the stock before 26 February 2026. Payment date: 01 May 2026. Payout ratio is a comfortable 33% but the company is paying out more than the cash it is generating. Trailing yield: 3.8%. Within top quartile of Japanese dividend payers (3.4%). Higher than average of industry peers (1.5%). Reported Earnings • Jan 10
Third quarter 2026 earnings released: EPS: JP¥74.35 (vs JP¥77.09 in 3Q 2025) Third quarter 2026 results: EPS: JP¥74.35 (down from JP¥77.09 in 3Q 2025). Revenue: JP¥13.9b (up 12% from 3Q 2025). Net income: JP¥280.0m (down 3.4% from 3Q 2025). Profit margin: 2.0% (down from 2.3% in 3Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. 공지 • Nov 27
Medical Ikkou Group Co.,Ltd. to Report Q3, 2026 Results on Jan 09, 2026 Medical Ikkou Group Co.,Ltd. announced that they will report Q3, 2026 results on Jan 09, 2026 Reported Earnings • Oct 07
Second quarter 2026 earnings released: EPS: JP¥60.58 (vs JP¥74.48 in 2Q 2025) Second quarter 2026 results: EPS: JP¥60.58 (down from JP¥74.48 in 2Q 2025). Revenue: JP¥13.5b (up 18% from 2Q 2025). Net income: JP¥228.0m (down 19% from 2Q 2025). Profit margin: 1.7% (down from 2.4% in 2Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. 공지 • Aug 27
Medical Ikkou Group Co.,Ltd. to Report Q2, 2026 Results on Oct 06, 2025 Medical Ikkou Group Co.,Ltd. announced that they will report Q2, 2026 results on Oct 06, 2025 Upcoming Dividend • Aug 21
Upcoming dividend of JP¥60.00 per share Eligible shareholders must have bought the stock before 28 August 2025. Payment date: 05 November 2025. Payout ratio is a comfortable 20% but the company is paying out more than the cash it is generating. Trailing yield: 3.6%. Lower than top quartile of Japanese dividend payers (3.7%). Higher than average of industry peers (1.6%). New Risk • Jul 14
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (275% cash payout ratio). Share price has been volatile over the past 3 months (5.5% average weekly change). Market cap is less than US$100m (JP¥12.2b market cap, or US$83.0m). Valuation Update With 7 Day Price Move • Jul 14
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to JP¥3,290, the stock trades at a trailing P/E ratio of 10.8x. Average trailing P/E is 13x in the Consumer Retailing industry in Japan. Total returns to shareholders of 26% over the past three years. Buy Or Sell Opportunity • Jul 14
Now 24% overvalued after recent price rise Over the last 90 days, the stock has risen 49% to JP¥3,290. The fair value is estimated to be JP¥2,645, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 16% over the last 3 years. Earnings per share has grown by 18%. Reported Earnings • Jul 09
First quarter 2026 earnings released: EPS: JP¥116 (vs JP¥114 in 1Q 2025) First quarter 2026 results: EPS: JP¥116 (up from JP¥114 in 1Q 2025). Revenue: JP¥13.4b (up 20% from 1Q 2025). Net income: JP¥438.0m (up 2.1% from 1Q 2025). Profit margin: 3.3% (down from 3.8% in 1Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. 공지 • May 27
Medical Ikkou Group Co.,Ltd. to Report Q1, 2026 Results on Jul 07, 2025 Medical Ikkou Group Co.,Ltd. announced that they will report Q1, 2026 results on Jul 07, 2025 Buy Or Sell Opportunity • Apr 10
Now 24% overvalued after recent price rise Over the last 90 days, the stock has risen 3.8% to JP¥2,274. The fair value is estimated to be JP¥1,830, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 14% over the last 3 years. Earnings per share has grown by 18%. New Risk • Apr 08
New minor risk - Dividend sustainability The dividend is not well covered by cash flows. Cash payout ratio: 115% Dividend yield: 2.3% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by cash flows (115% cash payout ratio). Market cap is less than US$100m (JP¥8.28b market cap, or US$56.0m). Reported Earnings • Apr 05
Full year 2025 earnings released: EPS: JP¥301 (vs JP¥276 in FY 2024) Full year 2025 results: EPS: JP¥301 (up from JP¥276 in FY 2024). Revenue: JP¥48.4b (up 21% from FY 2024). Net income: JP¥1.13b (up 9.0% from FY 2024). Profit margin: 2.3% (down from 2.6% in FY 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 8% per year, which means it is significantly lagging earnings. 공지 • Apr 04
Medical Ikkou Group Co.,Ltd., Annual General Meeting, May 21, 2025 Medical Ikkou Group Co.,Ltd., Annual General Meeting, May 21, 2025. Upcoming Dividend • Feb 20
Upcoming dividend of JP¥25.00 per share Eligible shareholders must have bought the stock before 27 February 2025. Payment date: 01 May 2025. Payout ratio is a comfortable 15% and this is well supported by cash flows. Trailing yield: 2.3%. Lower than top quartile of Japanese dividend payers (3.8%). Higher than average of industry peers (1.6%). Reported Earnings • Jan 15
Third quarter 2025 earnings released: EPS: JP¥77.09 (vs JP¥97.92 in 3Q 2024) Third quarter 2025 results: EPS: JP¥77.09 (down from JP¥97.92 in 3Q 2024). Revenue: JP¥12.4b (up 9.8% from 3Q 2024). Net income: JP¥290.0m (down 21% from 3Q 2024). Profit margin: 2.3% (down from 3.3% in 3Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 18% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. 공지 • Dec 21
Medical Ikkou Group Co.,Ltd. (TSE:3353) signed a letter of intent to acquire Shizuoka Sawai Yakuhin K.K. from Shinichi Takeshita. Medical Ikkou Group Co.,Ltd. (TSE:3353) signed a letter of intent to acquire Shizuoka Sawai Yakuhin K.K. from Shinichi Takeshita on December 20, 2024. A cash consideration will be paid by Medical Ikkou Group Co.,Ltd. As part of consideration, an undisclosed value is paid towards common equity of Shizuoka Sawai Yakuhin K.K.
The expected completion of the transaction is March 1, 2025. New Risk • Dec 16
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (JP¥7.28b market cap, or US$47.3m). 공지 • Oct 31
Medical Ikkou Group Co.,Ltd. to Report Q3, 2025 Results on Jan 10, 2025 Medical Ikkou Group Co.,Ltd. announced that they will report Q3, 2025 results on Jan 10, 2025 Reported Earnings • Oct 09
Second quarter 2025 earnings released: EPS: JP¥74.48 (vs JP¥62.01 in 2Q 2024) Second quarter 2025 results: EPS: JP¥74.48 (up from JP¥62.01 in 2Q 2024). Revenue: JP¥11.5b (up 32% from 2Q 2024). Net income: JP¥280.0m (up 20% from 2Q 2024). Profit margin: 2.4% (down from 2.7% in 2Q 2024). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 15% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. New Risk • Sep 17
New major risk - Financial data availability The company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risk Market cap is less than US$100m (JP¥8.52b market cap, or US$60.6m). Upcoming Dividend • Aug 22
Upcoming dividend of JP¥25.00 per share Eligible shareholders must have bought the stock before 29 August 2024. Payment date: 06 November 2024. Payout ratio is a comfortable 13% and this is well supported by cash flows. Trailing yield: 2.1%. Lower than top quartile of Japanese dividend payers (3.7%). Higher than average of industry peers (1.7%). Valuation Update With 7 Day Price Move • Aug 06
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to JP¥2,300, the stock trades at a trailing P/E ratio of 6.9x. Average trailing P/E is 12x in the Consumer Retailing industry in Japan. Total loss to shareholders of 14% over the past three years. 공지 • Aug 02
Medical Ikkou Group Co.,Ltd. to Report Q2, 2025 Results on Oct 07, 2024 Medical Ikkou Group Co.,Ltd. announced that they will report Q2, 2025 results on Oct 07, 2024 Board Change • Aug 01
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Outside Director Shigehiro Kuwabara was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Jul 10
First quarter 2025 earnings released: EPS: JP¥114 (vs JP¥56.16 in 1Q 2024) First quarter 2025 results: EPS: JP¥114 (up from JP¥56.16 in 1Q 2024). Revenue: JP¥11.2b (up 28% from 1Q 2024). Net income: JP¥429.0m (up 103% from 1Q 2024). Profit margin: 3.8% (up from 2.4% in 1Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Board Change • Jun 01
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Outside Director Shigehiro Kuwabara was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. 공지 • May 30
Medical Ikkou Group Co.,Ltd. to Report Q1, 2025 Results on Jul 08, 2024 Medical Ikkou Group Co.,Ltd. announced that they will report Q1, 2025 results on Jul 08, 2024 Reported Earnings • Apr 07
Full year 2024 earnings released: EPS: JP¥276 (vs JP¥202 in FY 2023) Full year 2024 results: EPS: JP¥276 (up from JP¥202 in FY 2023). Revenue: JP¥39.9b (up 18% from FY 2023). Net income: JP¥1.04b (up 37% from FY 2023). Profit margin: 2.6% (up from 2.2% in FY 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. 공지 • Mar 06
Medical Ikkou Group Co.,Ltd. to Report Fiscal Year 2024 Results on Apr 05, 2024 Medical Ikkou Group Co.,Ltd. announced that they will report fiscal year 2024 results on Apr 05, 2024 Upcoming Dividend • Feb 21
Upcoming dividend of JP¥20.00 per share Eligible shareholders must have bought the stock before 28 February 2024. Payment date: 01 May 2024. Payout ratio is a comfortable 15% and this is well supported by cash flows. Trailing yield: 1.8%. Lower than top quartile of Japanese dividend payers (3.3%). Higher than average of industry peers (1.5%). Reported Earnings • Jan 12
Third quarter 2024 earnings released: EPS: JP¥97.92 (vs JP¥59.36 in 3Q 2023) Third quarter 2024 results: EPS: JP¥97.92 (up from JP¥59.36 in 3Q 2023). Revenue: JP¥11.3b (up 34% from 3Q 2023). Net income: JP¥368.0m (up 65% from 3Q 2023). Profit margin: 3.3% (up from 2.6% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 11% per year, which means it is performing significantly worse than earnings. 공지 • Dec 17
Medical Ikkou Group Co.,Ltd. to Report Q3, 2024 Results on Jan 10, 2024 Medical Ikkou Group Co.,Ltd. announced that they will report Q3, 2024 results on Jan 10, 2024 Reported Earnings • Oct 05
Second quarter 2024 earnings released: EPS: JP¥62.01 (vs JP¥44.19 in 2Q 2023) Second quarter 2024 results: EPS: JP¥62.01 (up from JP¥44.19 in 2Q 2023). Revenue: JP¥8.73b (up 3.7% from 2Q 2023). Net income: JP¥233.0m (up 40% from 2Q 2023). Profit margin: 2.7% (up from 2.0% in 2Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 4% per year but the company’s share price has fallen by 13% per year, which means it is performing significantly worse than earnings. 공지 • Aug 30
Medical Ikkou Group Co.,Ltd. to Report Q2, 2024 Results on Oct 02, 2023 Medical Ikkou Group Co.,Ltd. announced that they will report Q2, 2024 results on Oct 02, 2023 Upcoming Dividend • Aug 23
Upcoming dividend of JP¥20.00 per share at 1.9% yield Eligible shareholders must have bought the stock before 30 August 2023. Payment date: 06 November 2023. Payout ratio is a comfortable 20% and this is well supported by cash flows. Trailing yield: 1.9%. Lower than top quartile of Japanese dividend payers (3.5%). Higher than average of industry peers (1.6%). 공지 • Aug 02
Medical Ikkou Group Co.,Ltd. (TSE:3353) entered into basic agreement to acquire 50% stake in Hakuai Nakai Ethical Pharmacy Co., Ltd. from Kanichi Eguchi. Medical Ikkou Group Co.,Ltd. (TSE:3353) entered into basic agreement to acquire 50% stake in Hakuai Nakai Ethical Pharmacy Co., Ltd. from Kanichi Eguchi on April 19, 2023. Reported Earnings • Jul 04
First quarter 2024 earnings released: EPS: JP¥56.16 (vs JP¥55.38 in 1Q 2023) First quarter 2024 results: EPS: JP¥56.16 (up from JP¥55.38 in 1Q 2023). Revenue: JP¥8.72b (up 1.8% from 1Q 2023). Net income: JP¥211.0m (up 1.4% from 1Q 2023). Profit margin: 2.4% (in line with 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 11% per year, which means it is performing significantly worse than earnings. 공지 • Jun 01
Medical Ikkou Group Co.,Ltd. to Report Q1, 2024 Results on Jul 03, 2023 Medical Ikkou Group Co.,Ltd. announced that they will report Q1, 2024 results on Jul 03, 2023 Reported Earnings • May 30
Full year 2023 earnings released: EPS: JP¥202 (vs JP¥227 in FY 2022) Full year 2023 results: EPS: JP¥202 (down from JP¥227 in FY 2022). Revenue: JP¥33.9b (flat on FY 2022). Net income: JP¥759.0m (down 11% from FY 2022). Profit margin: 2.2% (down from 2.5% in FY 2022). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 16% per year, which means it is performing significantly worse than earnings. Reported Earnings • Apr 08
Full year 2023 earnings released: EPS: JP¥202 (vs JP¥227 in FY 2022) Full year 2023 results: EPS: JP¥202 (down from JP¥227 in FY 2022). Revenue: JP¥33.9b (flat on FY 2022). Net income: JP¥759.0m (down 11% from FY 2022). Profit margin: 2.2% (down from 2.5% in FY 2022). Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has fallen by 6% per year. Upcoming Dividend • Feb 20
Upcoming dividend of JP¥20.00 per share at 1.5% yield Eligible shareholders must have bought the stock before 27 February 2023. Payment date: 02 May 2023. Payout ratio is a comfortable 19% and this is well supported by cash flows. Trailing yield: 1.5%. Lower than top quartile of Japanese dividend payers (3.6%). In line with average of industry peers (1.6%). 공지 • Feb 01
Medical Ikkou Group Co.,Ltd. to Report Fiscal Year 2023 Results on Apr 07, 2023 Medical Ikkou Group Co.,Ltd. announced that they will report fiscal year 2023 results on Apr 07, 2023 Reported Earnings • Jan 11
Third quarter 2023 earnings released: EPS: JP¥59.36 (vs JP¥59.90 in 3Q 2022) Third quarter 2023 results: EPS: JP¥59.36 (down from JP¥59.90 in 3Q 2022). Revenue: JP¥8.45b (flat on 3Q 2022). Net income: JP¥223.0m (flat on 3Q 2022). Profit margin: 2.6% (down from 2.7% in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Outside Director Keiko Horino was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. 공지 • Nov 13
Medical Ikkou Group Co.,Ltd. to Report Q3, 2023 Results on Jan 10, 2023 Medical Ikkou Group Co.,Ltd. announced that they will report Q3, 2023 results on Jan 10, 2023 Board Change • Oct 21
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Outside Director Keiko Horino was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 05
Second quarter 2023 earnings released: EPS: JP¥44.19 (vs JP¥58.31 in 2Q 2022) Second quarter 2023 results: EPS: JP¥44.19 (down from JP¥58.31 in 2Q 2022). Revenue: JP¥8.42b (up 1.3% from 2Q 2022). Net income: JP¥166.0m (down 24% from 2Q 2022). Profit margin: 2.0% (down from 2.6% in 2Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings. Upcoming Dividend • Aug 26
Upcoming dividend of JP¥20.00 per share Eligible shareholders must have bought the stock before 30 August 2022. Payment date: 04 November 2022. Payout ratio is a comfortable 18% and this is well supported by cash flows. Trailing yield: 1.5%. Lower than top quartile of Japanese dividend payers (3.6%). In line with average of industry peers (1.6%). Board Change • Aug 26
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 4 non-independent directors. Independent Outside Director Keiko Horino was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. 공지 • Aug 24
Medical Ikkou Group Co.,Ltd. to Report Q2, 2023 Results on Oct 03, 2022 Medical Ikkou Group Co.,Ltd. announced that they will report Q2, 2023 results on Oct 03, 2022 Reported Earnings • Jul 07
First quarter 2023 earnings released: EPS: JP¥55.38 (vs JP¥60.17 in 1Q 2022) First quarter 2023 results: EPS: JP¥55.38 (down from JP¥60.17 in 1Q 2022). Revenue: JP¥8.56b (flat on 1Q 2022). Net income: JP¥208.0m (down 8.0% from 1Q 2022). Profit margin: 2.4% (down from 2.7% in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. Reported Earnings • Jun 01
Full year 2022 earnings released: EPS: JP¥227 (vs JP¥222 in FY 2021) Full year 2022 results: EPS: JP¥227 (up from JP¥222 in FY 2021). Revenue: JP¥33.6b (up 6.3% from FY 2021). Net income: JP¥852.0m (up 1.9% from FY 2021). Profit margin: 2.5% (in line with FY 2021). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 15% per year, which means it is significantly lagging earnings. 공지 • May 26
Medical Ikkou Group Co.,Ltd. to Report Q1, 2023 Results on Jul 04, 2022 Medical Ikkou Group Co.,Ltd. announced that they will report Q1, 2023 results on Jul 04, 2022 Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Outside Director Keiko Horino was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Apr 10
Full year 2022 earnings released: EPS: JP¥227 (vs JP¥222 in FY 2021) Full year 2022 results: EPS: JP¥227 (up from JP¥222 in FY 2021). Revenue: JP¥33.6b (up 6.3% from FY 2021). Net income: JP¥852.0m (up 1.9% from FY 2021). Profit margin: 2.5% (in line with FY 2021). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings. 공지 • Feb 27
Medical Ikkou Group Co.,Ltd. to Report Fiscal Year 2022 Results on Apr 08, 2022 Medical Ikkou Group Co.,Ltd. announced that they will report fiscal year 2022 results on Apr 08, 2022 Upcoming Dividend • Feb 18
Upcoming dividend of JP¥20.00 per share Eligible shareholders must have bought the stock before 25 February 2022. Payment date: 06 May 2022. Payout ratio is a comfortable 37% and this is well supported by cash flows. Trailing yield: 1.6%. Lower than top quartile of Japanese dividend payers (3.4%). In line with average of industry peers (1.6%). Reported Earnings • Jan 12
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: EPS: JP¥59.90 (down from JP¥67.35 in 3Q 2021). Revenue: JP¥8.40b (up 5.5% from 3Q 2021). Net income: JP¥225.0m (down 11% from 3Q 2021). Profit margin: 2.7% (down from 3.2% in 3Q 2021). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings. Reported Earnings • Oct 01
Second quarter 2022 earnings released: EPS JP¥58.31 (vs JP¥77.54 in 2Q 2021) The company reported a soft second quarter result with weaker earnings and profit margins, although revenues improved. Second quarter 2022 results: Revenue: JP¥8.31b (up 7.9% from 2Q 2021). Net income: JP¥219.0m (down 25% from 2Q 2021). Profit margin: 2.6% (down from 3.8% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings. Upcoming Dividend • Aug 23
Upcoming dividend of JP¥20.00 per share Eligible shareholders must have bought the stock before 30 August 2021. Payment date: 04 November 2021. Trailing yield: 1.5%. Lower than top quartile of Japanese dividend payers (3.1%). In line with average of industry peers (1.4%). Board Change • Aug 19
Less than half of directors are independent Following the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 5 non-independent directors. Full-Time Auditor Takashi Fukushima was the last director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Jul 10
First quarter 2022 earnings released: EPS JP¥60.17 (vs JP¥37.25 in 1Q 2021) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: JP¥8.51b (up 8.7% from 1Q 2021). Net income: JP¥226.0m (up 59% from 1Q 2021). Profit margin: 2.7% (up from 1.8% in 1Q 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 17% per year, which means it is performing significantly worse than earnings. Reported Earnings • May 30
Full year 2021 earnings released: EPS JP¥443 (vs JP¥210 in FY 2020) The company reported a mediocre full year result with weaker revenues, although profit margins were flat and earnings improved. Full year 2021 results: Revenue: JP¥31.6b (down 1.4% from FY 2020). Net income: JP¥836.0m (up 4.4% from FY 2020). Profit margin: 2.6% (in line with FY 2020). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings. Reported Earnings • Apr 15
Full year 2021 earnings released: EPS JP¥443 (vs JP¥210 in FY 2020) The company reported a mediocre full year result with weaker revenues, although profit margins were flat and earnings improved. Full year 2021 results: Revenue: JP¥31.6b (down 1.4% from FY 2020). Net income: JP¥836.0m (up 4.4% from FY 2020). Profit margin: 2.6% (in line with FY 2020). Over the last 3 years on average, earnings per share has increased by 3% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Is New 90 Day High Low • Mar 11
New 90-day low: JP¥2,990 The company is down 9.0% from its price of JP¥3,290 on 10 December 2020. The Japanese market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Consumer Retailing industry, which is up 4.0% over the same period. Reported Earnings • Jan 15
Third quarter 2021 earnings released: EPS JP¥135 The company reported a decent third quarter result with improved earnings and profit margins, although revenues were flat. Third quarter 2021 results: Revenue: JP¥7.96b (flat on 3Q 2020). Net income: JP¥253.0m (up 28% from 3Q 2020). Profit margin: 3.2% (up from 2.5% in 3Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 17% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings. 공지 • Jan 08
Medical Ikkou Group Co.,Ltd. to Report Q3, 2021 Results on Jan 13, 2021 Medical Ikkou Group Co.,Ltd. announced that they will report Q3, 2021 results on Jan 13, 2021 Valuation Update With 7 Day Price Move • Dec 03
Market bids up stock over the past week After last week's 15% share price gain to JP¥7,180, the stock is trading at a trailing P/E ratio of 16.3x, up from the previous P/E ratio of 14.1x. This compares to an average P/E of 16x in the Consumer Retailing industry in Japan. Total return to shareholders over the past three years is a loss of 13%. Reported Earnings • Oct 17
First half earnings released Over the last 12 months the company has reported total profits of JP¥838.0m, up 16% from the prior year. Total revenue was JP¥31.5b over the last 12 months, largely unchanged from the prior year. 공지 • Oct 04
Medical Ikkou Group Co.,Ltd. to Report Q2, 2021 Results on Sep 30, 2020 Medical Ikkou Group Co.,Ltd. announced that they will report Q2, 2021 results on Sep 30, 2020 Reported Earnings • Oct 01
First half earnings released Over the last 12 months the company has reported total profits of JP¥838.0m, up 16% from the prior year. Total revenue was JP¥31.5b over the last 12 months, largely unchanged from the prior year. 공지 • Jun 28
Medical Ikkou Group Co.,Ltd. to Report Q1, 2021 Results on Jul 06, 2020 Medical Ikkou Group Co.,Ltd. announced that they will report Q1, 2021 results on Jul 06, 2020